ES2908345T3 - Líquidos iónicos para la administración transdérmica de medicamentos - Google Patents

Líquidos iónicos para la administración transdérmica de medicamentos Download PDF

Info

Publication number
ES2908345T3
ES2908345T3 ES14859243T ES14859243T ES2908345T3 ES 2908345 T3 ES2908345 T3 ES 2908345T3 ES 14859243 T ES14859243 T ES 14859243T ES 14859243 T ES14859243 T ES 14859243T ES 2908345 T3 ES2908345 T3 ES 2908345T3
Authority
ES
Spain
Prior art keywords
acid
composition
skin
choline
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14859243T
Other languages
English (en)
Spanish (es)
Inventor
Michael Zakrewsky
Samir Mitragotri
david t Fox
Andrew Koppisch
Sesto Rico Del
Katherine Lovejoy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Triad National Security LLC
Arizona's Public Universities
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Triad National Security LLC
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD, Triad National Security LLC, Arizona's Public Universities filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2908345T3 publication Critical patent/ES2908345T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02Amines; Quaternary ammonium compounds
    • A01N33/12Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Insects & Arthropods (AREA)
ES14859243T 2013-11-03 2014-11-03 Líquidos iónicos para la administración transdérmica de medicamentos Active ES2908345T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899294P 2013-11-03 2013-11-03
PCT/US2014/063745 WO2015066647A2 (en) 2013-11-03 2014-11-03 Ionic liquids for transdermal drug delivery

Publications (1)

Publication Number Publication Date
ES2908345T3 true ES2908345T3 (es) 2022-04-28

Family

ID=53005413

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14859243T Active ES2908345T3 (es) 2013-11-03 2014-11-03 Líquidos iónicos para la administración transdérmica de medicamentos

Country Status (7)

Country Link
US (3) US10449254B2 (OSRAM)
EP (1) EP3062819B1 (OSRAM)
JP (3) JP2016535781A (OSRAM)
KR (1) KR102286115B1 (OSRAM)
CA (2) CA3100536A1 (OSRAM)
ES (1) ES2908345T3 (OSRAM)
WO (1) WO2015066647A2 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
EP3395369A1 (en) * 2014-10-30 2018-10-31 Asahi Kasei Kabushiki Kaisha Transdermal absorption enhancer and transdermal absorption enhancement aid
CA2931913C (en) 2015-06-12 2024-03-19 Kemira Oyj Bitumen separation using ionic liquids comprising unsubstituted or substituted primary, secondary or tertiary amines, pyridines, amidines, guanidines and fatty acids and/or resin acids
KR102552848B1 (ko) * 2016-08-29 2023-07-06 더 리전츠 오브 더 유니버시티 오브 캘리포니아 피부 치료를 위한 이온성 약제에 기초한 국소 제형
US11274137B1 (en) * 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery
WO2018222924A1 (en) * 2017-06-01 2018-12-06 Arizona Board Of Regents On Behalf Of Northern Arizona University Antibiofilm formulations
JP7425726B2 (ja) * 2017-11-17 2024-01-31 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 体内送達のためのイオン液体
JP2019131480A (ja) * 2018-01-29 2019-08-08 旭化成株式会社 経皮吸収促進剤及び経皮製剤
US20210113696A1 (en) * 2018-03-19 2021-04-22 Cage Bio Inc. Ionic liquid compositions for treatment of rosacea
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR101959524B1 (ko) * 2018-09-19 2019-03-18 주식회사 우신라보타치 리도카인을 포함한 이온토포레시스용 점착성 카타플라스마 시스템
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
KR20220004066A (ko) * 2019-04-03 2022-01-11 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 약물 전달용 이온성 액체
ES2912262T3 (es) * 2019-05-29 2022-05-25 Hopitaux Paris Assist Publique Sistema eutéctico de las catequinas del té verde
AU2020378151A1 (en) * 2019-11-08 2022-05-26 Cage Bio, Inc. Topical delivery of tofacitinib using ionic liquid
IL293145A (en) 2019-11-22 2022-07-01 Harvard College Ionic liquids for drug delivery
WO2021119198A1 (en) * 2019-12-09 2021-06-17 Cage Bio, Inc. Topical delivery of rna interference agents using ionic liquid
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
US20230329988A1 (en) * 2020-06-26 2023-10-19 Cage Bio Inc. Sanitizing compositions containing ionic liquid
EP4225324A4 (en) * 2020-10-05 2024-11-13 Cage Bio Inc. IONIC LIQUID COMPOSITIONS FOR SKIN DISEASES AND CONDITIONS
CN116322658B (zh) * 2020-10-29 2025-09-26 久光制药株式会社 含罗匹尼罗的贴附剂及罗匹尼罗的皮肤透过性的提升方法
AU2021379265A1 (en) * 2020-11-13 2023-06-01 Universidade Do Minho Eutectic compositions, methods and uses thereof
WO2022256291A1 (en) 2021-06-01 2022-12-08 President And Fellows Of Harvard College Hydrogel devices for drug delivery to the ear
WO2022271537A1 (en) 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
US12005134B2 (en) 2021-06-30 2024-06-11 Abe Pharmaceutical Composition for stimulating facial hair growth and methods of manufacturing a composition for stimulating facial hair growth
IL311885A (en) 2021-10-08 2024-06-01 Harvard College Ionic liquids for drug delivery
JP2024544920A (ja) 2021-11-10 2024-12-05 アイ2オー セラピューティクス,インク. イオン液体組成物
CN116474153B (zh) * 2022-01-17 2024-09-27 四川大学 一种基于竹纤维-低共熔溶剂-明胶的皮肤溃疡护理贴膜
US12109303B2 (en) 2022-04-18 2024-10-08 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions and methods of their use
CN115671285B (zh) * 2022-08-24 2024-01-05 上海市皮肤病医院 一种抗真菌溶液及其制备方法和应用
WO2025147130A1 (ko) * 2024-01-03 2025-07-10 주식회사 바이온리퀴드 이온성 액체 또는 공융 용매를 이용한 신규 약물제형

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342840A (en) * 1964-03-23 1967-09-19 Shell Oil Co Cationic ester production
US4042327A (en) 1976-01-15 1977-08-16 Waters Associates, Inc. Ion-pairing chromatography
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JPS62209523A (ja) 1986-03-11 1987-09-14 Fuji Photo Film Co Ltd 感光材料
US4892737A (en) * 1988-09-22 1990-01-09 University Of Florida Composition and method for enhancing permeability of topical drugs
HU203372B (en) 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
KR100356882B1 (ko) * 1994-03-28 2003-03-10 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 글루콘산아연 겔 조성물
JP4236281B2 (ja) 1995-06-07 2009-03-11 ジェン−プローブ・インコーポレーテッド ミセル保護アッセイ
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
CA2471414C (en) 2001-12-21 2011-11-01 Rhodia Inc. Combined stable cationic and anionic surfactant compositions
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US6858217B2 (en) * 2002-03-22 2005-02-22 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stabilization of terpenoids in cosmetic compositions
EP1661560B1 (en) 2004-11-22 2008-11-05 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch comprising a melting point lowering agent
US9139850B2 (en) 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
WO2007124397A2 (en) 2006-04-21 2007-11-01 Trustees Of Boston University Ionic viscoelastics and viscoelastic salts
WO2008031105A1 (en) * 2006-09-08 2008-03-13 Delaval Holdings Ab Polymeric guanidine salt-based germicides
JP5117732B2 (ja) * 2007-01-29 2013-01-16 株式会社 メドレックス 外用剤用の低刺激性溶解助剤
JP4952272B2 (ja) 2007-01-29 2012-06-13 株式会社ツムラ (z)−リグスチリドの製造方法
US8247198B2 (en) 2007-09-21 2012-08-21 Friedrich Srienc Enzymatic processing in deep eutectic solvents
US8623387B2 (en) 2007-11-22 2014-01-07 Medrx Co., Ltd. External preparation composition comprising fatty acid-based ionic liquid as active ingredient
US8022014B2 (en) 2008-03-26 2011-09-20 Shrieve Chemical Products, Inc. Deep eutectic solvents and applications
JP5681883B2 (ja) 2009-03-27 2015-03-11 株式会社 メドレックス 核酸を有効成分とする外用剤組成物
WO2011056545A2 (en) * 2009-10-26 2011-05-12 Trustees Of Boston University Antimicrobial ionic liquids
WO2011057209A1 (en) 2009-11-06 2011-05-12 Qlt, Inc. Acidic ophthalmic formulations
NO2510096T3 (OSRAM) 2009-12-10 2015-03-21
WO2013064583A1 (en) 2011-11-04 2013-05-10 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
EP2597099B1 (en) 2011-11-23 2018-08-15 King Saud University Deep eutectic solvent and method for its preparation
EP2740484A1 (en) 2012-12-05 2014-06-11 Lipotec, S.A. Compounds useful in the treatment and/or care of the skin, hair and/or muccous membranes and their cosmetic or pharmaceutical compositions
FR3002452B1 (fr) 2013-02-28 2016-02-12 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
CN105434337B (zh) 2015-04-03 2019-08-16 武汉科福新药有限责任公司 盐酸普萘洛尔亚微乳凝胶及其制备方法和用途

Also Published As

Publication number Publication date
JP2020097633A (ja) 2020-06-25
US11786597B2 (en) 2023-10-17
WO2015066647A3 (en) 2015-06-18
US20160263225A1 (en) 2016-09-15
US10449254B2 (en) 2019-10-22
EP3062819B1 (en) 2021-12-22
JP2016535781A (ja) 2016-11-17
WO2015066647A9 (en) 2015-09-17
US20190388545A1 (en) 2019-12-26
CA3100536A1 (en) 2015-05-07
EP3062819A4 (en) 2017-09-27
JP6674058B2 (ja) 2020-04-01
EP3062819A2 (en) 2016-09-07
CA2929630C (en) 2021-01-12
US20240156964A1 (en) 2024-05-16
KR20160097202A (ko) 2016-08-17
KR102286115B1 (ko) 2021-08-04
JP2019073561A (ja) 2019-05-16
WO2015066647A2 (en) 2015-05-07
CA2929630A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
ES2908345T3 (es) Líquidos iónicos para la administración transdérmica de medicamentos
Vigani et al. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes
ES2863125T3 (es) Microcápsulas que comprenden agentes de filtros solares
ES2591030T3 (es) Composición farmacéutica antifúngica
ES2557475T3 (es) Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
KR101351771B1 (ko) 바람직하게 saib와 같은 당 에스테르를 포함하는지속적인 국소 마취제 조성물
EP2961433A1 (en) Peptide-based hydrogel particles and uses thereof
US20150238435A1 (en) Oral Drug Devices and Drug Formulations
AU2010238574A1 (en) Compositions for intratumoral administration
US9919016B2 (en) Product and method of deploying kale derivatives for anti-cancer effects
WO2014160404A1 (en) Improved oral drug devices and drug formulations
US20160000881A1 (en) Oral Drug Devices and Drug Formulations
ES2989981T3 (es) Combinación de fármacos y su uso en el tratamiento del cáncer
US20220211638A1 (en) Products of manufacture and methods for transdermal delivery of pharmaceuticals, electrolytes, and nutriceuticals
WO2021145795A2 (ru) Биоадгезивное антибактериальное средство, способ его изготовления (варианты)
CN101247834B (zh) 包含一种或多种二-和/或单-(电子转移剂)磷酸酯衍生物或其络合物的载体
WO2018178497A2 (es) Uso de melatonina para el tratamiento de tumores
BR102025001090A2 (pt) Método para preparar uma amostra de sangue com início tardio ou progressão retardada de lesão de armazenamento de hemácias ex vivo na amostra durante o armazenamento, amostra de sangue ex vivo, e método para transfusão de sangue
BR122025001904A2 (pt) Método para preparar uma amostra de sangue com início tardio ou progressão retardada de lesão de armazenamento de hemácias ex vivo na amostra durante o armazenamento, amostra de sangue ex vivo e seu uso
WO2018176168A1 (es) Bioproducto a base de nanopartículas de selenio en matriz miel, para el tratamiento de heridas complejas e infecciones dermatológicas
WO2012107602A1 (es) Forma de administración de fosfolípidos para la formación sobre la piel de capas laminares de fosfolípidos
JPWO2008081590A1 (ja) 医療用組成物